Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Diseases of the Colon and Rectum|December 11, 2012
Factors associated with symptom severity in women presenting with fecal incontinenceS B Menees, T M Smith, X Xu, et al.
Neurogastroenterology and Motility|March 26, 2018
Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrheaD M Brenner, L S Dove, D A Andrae, et al.
Alimentary Pharmacology & Therapeutics|November 14, 2008
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studiesD A Drossman, W D Chey, J F Johanson, et al.
Gastrointestinal Endoscopy|March 25, 1998
Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended currentG H Elta, J L Barnett, R T Wille, et al.
The American Journal of Physiology|September 2, 1998
Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humansA B Gorelick, S S Koshy, F G Hooper, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux diseaseR Fass, W D Chey, S F Zakko, et al.
Alimentary Pharmacology & Therapeutics|January 7, 2014
A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leadsM P Jones, W D Chey, S Singh, et al.
The American Journal of Physiology|September 2, 1998
Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflexE S Björnsson, W D Chey, U Ladabaum, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2008
The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux diseaseB Nojkov, J H Rubenstein, S A Adlis, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2014
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trialsP Schoenfeld, M Pimentel, L Chang, et al.
Pageof 7